Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Inhibition of Bromodomain and Extraterminal Domain (BET) Proteins Alleviates Chronic Graft- Versus -Host-Disease Via Modulating the CXCR5/CXCL13 Axis

Rathan Kumar, Lotus Neidermire-Colley, Charlie Spencer, David Aslaner, Yandi Gao, Simran Surana, Matthew W Gorr, Katiri Snyder, Malith Karunasiri, Loren E Wold, Gideon Bollag, Ben Powell, Hannah Choe, Parvathi Ranganathan

Blood (2023) 142 (Supplement 1): 2047.

https://doi.org/10.1182/blood-2023-182354

Published: 2023

Journal Articles

BET Inhibition As a Targeted Epigenetic Approach to Reverse T Cell Dysfunction in Chronic Lymphocytic Leukemia

Audrey L Smith, Alexandria P Eiken, Sydney A Skupa, Dalia Y Moore, Avyakta Kallam, Christopher D'Angelo, Gregory R Bociek, Matthew A. Lunning, Julie M. Vose, Ben Powell, Gideon Bollag, Dalia ElGamal

Blood (2021) 138 (Supplement 1): 3715.

https://doi.org/10.1182/blood-2021-153921

Published: 2021

Journal Articles

Co-Targeting BET Bromodomain Proteins and Aberrant Signaling in AML

Benjamin J. Huang, MD, Xinyue Wang, BA, Max Harris, BA, Anica Wandler, PhD, Eugene Hwang, BA, Michael R. Burgess, MD PhD, Qing Li, MD PhD, Paul Severson, PhD, Ben Powell, PhD, Edward A. Kolb, MD, Soheil Meshinchi, MDPhD, Barry S Taylor, PhD, Gideon Bollag, PhD, Kevin M. Shannon, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-142921

Published: 2020

Journal Articles

Bromodomain and Extraterminal (BET) Domain Inhibition with PLX51107 and PLX2853 Improves Survival and Decreases Acute GVHD Severity in Murine Models

Hannah K. Choe, MD, Yandi Gao, MS, Katiri Snyder, BS, Ben Powell, PhD, Gideon Bollag, PhD, Parvathi Ranganathan, PhD

Blood (2019) 134 (Supplement_1): 4429.

https://doi.org/10.1182/blood-2019-122455

Published: 2019

Journal Articles

A Novel Combination Regimen of BET and FLT3 Inhibition for FLT3-ITD Acute Myeloid Leukemia

Lauren Lee, Yoshiyuki Hizukuri, Paul Severson, Ben Powell, PhD, Chao Zhang, PhD, Yan Ma, Maiko Narahara, Hiroyuki Sumi, PhD, Gideon Bollag, PhD, Mark J. Levis, MD

Blood (2019) 134 (Supplement_1): 1373.

https://doi.org/10.1182/blood-2019-124030

Published: 2019

Journal Articles

A Mixed Type 1 and Type 2 Kinase Inhibitor That Overrides FLT3 F691 and D835 Resistance Mutations

Jack Lin, PhD, Ying Zhang, PhD, Bernice Matusow, Adam Mumy, Garson Tsang, Jiazhong Zhang, PhD, Hannah Powers, Wayne Spevak, PhD, Paul Severson, PhD, James Tsai, Gideon Bollag, PhD, Chao Zhang, PhD

Blood (2016) 128 (22): 1074.

https://doi.org/10.1182/blood.V128.22.1074.1074

Published: 2016

Journal Articles

Response and Resistance to Bromodomain Inhibition in AML Driven By Hyperactive Ras Signaling

Benjamin Huang, MD, Eugene Hwang, Anica M. Wandler, PhD, Ben Powell, PhD, Gideon Bollag, PhD, Kevin Shannon, MD

Blood (2016) 128 (22): 1654.

https://doi.org/10.1182/blood.V128.22.1654.1654

Published: 2016

Journal Articles

Recurrent Mutations in CCND3 Confer Clinical Resistance to FLT3 Inhibitors

Catherine C. Smith, MD, Aaron D. Viny, MD MS, Evan S. Massi, BS, Cyriac Kandoth, PhD, Nicholas D. Socci, PhD, Henry Hsu, MD, Brian West, PhD, Gideon Bollag, PhD, Barry S. Taylor, PhD, Ross L. Levine, MD, Neil P. Shah

Blood (2015) 126 (23): 677.

https://doi.org/10.1182/blood.V126.23.677.677

Published: 2015

Journal Articles

The Combination of PLX3397, a Selective FLT3-ITD Inhibitor, and Decitabine, a Hypomethylating Agent, Demonstrates Benefit in AML Cell Lines in Vitro and in Vivo

James Tsai, Elizabeth A Burton, PhD, Gaston Habets, PhD, Brian West, PhD, Paul Lin, MD, Henry Hsu, MD, Chao Zhang, PhD, Gideon Bollag, PhD

Blood (2014) 124 (21): 3743.

https://doi.org/10.1182/blood.V124.21.3743.3743

Published: 2014

Journal Articles

Biochemical and Functional Analysis of Novel KRAS Insertions in MPN and Other Cancers

Yasmine N White, Aditi Bagchi, Jessica Van Ziffle, PhD, Gideon Bollag, PhD, Chao Zhang, PhD, David S Dickens, MD, Mignon L. Loh, MD, Kevin Shannon, MD, Ari J Firestone, PhD

Blood (2014) 124 (21): 2207.

https://doi.org/10.1182/blood.V124.21.2207.2207

Published: 2014

Journal Articles

The Novel Inhibitor PLX3397 Effectively Inhibits FLT3-Mutant AML,

Elizabeth Burton, Ph.D., Bernice Wong, Jiazhong Zhang, Ph.D., Brian West, Ph.D., Gideon Bollag, Ph.D., Gaston Habets, Ph.D., Allison Galanis, Hoa Nguyen, Omotayo Arowojolu, Trivikram Rajhowa, Mark J. Levis, MD, PhD

Blood (2011) 118 (21): 3632.

https://doi.org/10.1182/blood.V118.21.3632.3632

Published: 2011

Journal Articles

Akt Activation Is Important In KRAS-Mediated Multistep Leukemogenesis

Ashley F. Ward, MD, Angell Shieh, MD, Emily Rose Harding-Theobald, BA, Gideon Bollag, PhD, Kevin Shannon, MD

Blood (2010) 116 (21): 4200.

https://doi.org/10.1182/blood.V116.21.4200.4200

Published: 2010

Journal Articles

Biochemical and Functional Analysis of Germline KRAS Mutations That Cause Disorders of the Noonan Syndrome Spectrum.

Suzanne Schubbert, Oddmund Sovik, Gideon Bollag, Hoa Nguyen, Sara L. Rowe, Christian Kratz, Martin M. Zenker, Charlotte Marie Niemeyer, Anders Molven, Kevin Shannon

Blood (2006) 108 (11): 1431.

https://doi.org/10.1182/blood.V108.11.1431.1431

Published: 2006

Journal Articles

Novel Germ Line Mutations in the KRAS2 Gene Cause Noonan Syndrome and Deregulate Hematopoietic Cell Growth.

Suzanne Schubbert, Martin Zenker, MD, Sara L. Rowe, Silke Böll, Cornelia Klein, Ineke van der Burgt, MD, Luciana Musante, PhD, Hoa Nguyen, Brian West, PhD, Gideon Bollag, PhD, Charlotte M. Niemeyer, MD, Kevin M. Shannon, MD, Christian P. Kratz, MD

Blood (2005) 106 (11): 1602.

https://doi.org/10.1182/blood.V106.11.1602.1602

Published: 2005

Journal Articles

The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT–dependent apoptosis in diffuse large B-cell lymphoma

Peter G. Smith, Fengfei Wang, Kathryn N. Wilkinson, Kerry J. Savage, Ulf Klein, Donna S. Neuberg, Gideon Bollag, Margaret A. Shipp, Ricardo C. T. Aguiar

Blood (2005) 105 (1): 308–316.

https://doi.org/10.1182/blood-2004-01-0240

Published: 2005

Includes: Supplemental data

NARROW

Inhibition of Bromodomain and Extraterminal Domain (BET) Proteins Alleviates Chronic Graft- Versus -Host-Disease Via Modulating the CXCR5/CXCL13 Axis

BET Inhibition As a Targeted Epigenetic Approach to Reverse T Cell Dysfunction in Chronic Lymphocytic Leukemia

Co-Targeting BET Bromodomain Proteins and Aberrant Signaling in AML

Bromodomain and Extraterminal (BET) Domain Inhibition with PLX51107 and PLX2853 Improves Survival and Decreases Acute GVHD Severity in Murine Models

A Novel Combination Regimen of BET and FLT3 Inhibition for FLT3-ITD Acute Myeloid Leukemia

A Mixed Type 1 and Type 2 Kinase Inhibitor That Overrides FLT3 F691 and D835 Resistance Mutations

Response and Resistance to Bromodomain Inhibition in AML Driven By Hyperactive Ras Signaling

Recurrent Mutations in CCND3 Confer Clinical Resistance to FLT3 Inhibitors

The Combination of PLX3397, a Selective FLT3-ITD Inhibitor, and Decitabine, a Hypomethylating Agent, Demonstrates Benefit in AML Cell Lines in Vitro and in Vivo

Biochemical and Functional Analysis of Novel KRAS Insertions in MPN and Other Cancers

The Novel Inhibitor PLX3397 Effectively Inhibits FLT3-Mutant AML,

Akt Activation Is Important In KRAS-Mediated Multistep Leukemogenesis

Biochemical and Functional Analysis of Germline KRAS Mutations That Cause Disorders of the Noonan Syndrome Spectrum.

Novel Germ Line Mutations in the KRAS2 Gene Cause Noonan Syndrome and Deregulate Hematopoietic Cell Growth.

The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT–dependent apoptosis in diffuse large B-cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only